GLPwatch
Liraglutide for Low-responders After Bariatric Surgery
NCT04643301 · Withdrawn
Last updated 2026-05-28This clinical trial is testing whether the medication liraglutide can help people who have not lost enough weight after bariatric surgery.
Status Withdrawn Stopped before any participant enrolled.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design open-label (no blinding) study
Who can join Ages 18–75 · all sexes
Timeline Started 2020-12 · est. completion 2021-12
What this study is testing ClinicalTrials.gov NCT04643301 ↗
Description as written by the study sponsor.
To study the effect of Liraglutide (3.0 mg daily) on 9-month weight loss in low responders 3-months after bariatric surgery.
Treatments tested
- Liraglutide Pen Injector also known as Saxenda Drug
Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.
| Main thing measured | %TWL (%TWL) |
|---|---|
| Sponsor | Zuyderland Medisch Centrum |
| Conditions studied | Obesity, Obesity, Morbid |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04643301 ↗